Risk of misinterpretation of ebola virus PCR results after rVSV ZEBOV-GP vaccination

Clinical Infectious Diseases

Volumn 60, Issue 11, 2015, Pages 1725-1726

  Cnops, Lieselotte ^a   Gerard, Michèle ^b   Vandenberg, Olivier ^b   Van Den Wijngaert, Sigi ^b   Heyndrickx, Leo ^a   Willems, Elisabeth ^a   Demeulemeester, Kathy ^a   De Clerck, Hilde ^c   Dediste, Anne ^b   Callens, Steven ^d   De Munter, Paul ^e   Vlieghe, Erika ^a,f   Bottieau, Emmanuel ^a   Wuillaume, Francoise ^g   Van Esbroeck, Marjan ^a   Ariën, Kevin K ^a  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^c Operational Center Brussels   (Belgium)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f Federal Public Service Health   (Belgium)

^g Federal Agency for Medicines and Health Products Belgium   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EBOLA VACCINE; RECOMBINANT VACCINE; RECOMBINANT VESICULAR STOMATITIS VIRUS ZAIRE EBOLA VIRUS GLYCOPROTEIN VACCINE; UNCLASSIFIED DRUG;

BLOOD SAMPLING; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; FEVER; GENE SEQUENCE; HUMAN; LETTER; NONHUMAN; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; STRUCTURAL GENE; VACCINATION; CASE REPORT; FEMALE; GENETICS; HEMORRHAGIC FEVER, EBOLA; ISOLATION AND PURIFICATION; LABORATORY DIAGNOSIS; MOLECULAR DIAGNOSIS; POLYMERASE CHAIN REACTION; PROCEDURES; VIROLOGY;

EBOLA VACCINES; EBOLAVIRUS; FALSE POSITIVE REACTIONS; FEMALE; HEMORRHAGIC FEVER, EBOLA; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; POLYMERASE CHAIN REACTION; VACCINATION;

EID: 84930409629     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ131     Document Type: Letter

References (10)

1. Feldmann H, Jones SM, Daddario-Dicaprio KM, et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog 2007; 3:e2.
2. Günther S, Feldmann H, Geisbert TW, et al. B of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis 2011; 204: S785-90.
3. ECDC. Available at: http://www.ecdc.europa. B/en/healthtopics/ebola-marburg-fevers/ algorithm-evd-diagnosis/Pages/default.aspx. Accessed 4 February 2015.
4. Gibb TR, Norwood DA Jr, Woollen N, Henchal EA. Development and evaluation of a fluorogenic 5' nuclease assay to detect and differentiate between Ebola virus subtypes Zaire and Sudan. J Clin Microbiol 2001; 39:4125-30.
5. Panning M, Laue T, Olschlager S, et al. B reverse-transcription polymerase chain reaction kit for filoviruses based on the strain collections of all European biosafety level 4 laboratories. J Infect Dis 2007; 196: S199-204.
6. Baize S, Pannetier D, Oestereich L, et al. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med 2014; 371: 1418-25.
7. Piot P, Muyembe JJ, Edmunds WJ. Ebola in West Africa: from disease outbreak to humanitarian crisis. Lancet Infect Dis 2014; 14:1034-5.
8. WHO. Ebola response roadmap-situation report. Available at: http://www.who.int/csr/dis ease/ebola/situation-reports/en/?m=20141217. Accessed 4 February 2015.
9. Geisbert TW, Bailey M, Hensley L, et al. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J Virol 2011; 85:4222-33.
10. Zahn R, Gillisen G, Roos A, et al. Ad35 and Ad26 vaccine vectors induce potent and cross-reactive antibody and T cell responses to multiple filovirus species. PLoS One 2012; 7:e44115.